Full Text View
Tabular View
No Study Results Posted
Related Studies
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease
This study has been completed.
Study NCT00815919   Information provided by Dana-Farber Cancer Institute

First Received on December 30, 2008.   Last Updated on January 28, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Graft Versus Host Disease
Additional conditions recognized in this trial
Graft vs Host Disease
More general conditions related to this trial
Immune System Diseases
Interventions listed in this trial
bortezomib
Prednisone
More general drug interventions related to this trial
Anti-Inflammatory Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Enzyme Inhibitors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services